Eledon Pharmaceuticals (ELDN)
Bull Thesis
- Breakthrough islet data: All 10 evaluable T1D patients achieved 100% insulin independence after islet transplantation with tegoprubart, with stable graft function up to 22 months post-transplant.6
- Phase 2 BESTOW positive: Kidney transplant trial showed favorable safety vs. tacrolimus, with mean 12-month eGFR ~69 mL/min/1.73 m², supporting Phase 3 advancement.9
- Strong analyst conviction: 7 analysts rate ELDN Strong Buy with a median price target of $8.50 (implying ~138% upside from ~$3.57).2
- Funded through key milestones: $111.1M cash as of Q1 2026 funds operations into Q2 2027, covering Phase 3 FDA discussions and trial initiation.3
- Multiple indication optionality: Tegoprubart targets kidney, islet, liver, xenotransplantation, and ALS — five potential indications with Orphan Drug Designation granted in liver transplantation.10
Bear Thesis
- No revenue, indefinite losses: Eledon has generated no product revenue and posted a $39.0M net loss in Q1 2026 alone, with operations entirely dependent on external capital.3
- Cash runway expires Q2 2027: Without Phase 3 data or a partnership deal, the company will require additional equity or debt financing, likely dilutive at current share price levels.3
- Significant dilution history: Shares outstanding grew ~52% year-over-year, with an $85M underwritten offering priced at $3.65/share in late 2025 causing immediate book dilution of $1.50/share.11
- Phase 3 risk and timeline uncertainty: Phase 3 kidney transplant trial has not yet been initiated; FDA guidance is still pending, and any clinical setback or endpoint miss would be stock-devastating.7
- CD40L class safety history: Earlier-generation anti-CD40L antibodies were associated with thromboembolic complications; tegoprubart is designed to mitigate this, but long-term safety at scale remains unproven.12
Executive Summary
Eledon Pharmaceuticals (Nasdaq: ELDN) is a clinical-stage biopharmaceutical company developing tegoprubart, a next-generation anti-CD40 Ligand (CD40L) monoclonal antibody designed to provide immunosuppression without the toxicity profile of calcineurin inhibitors like tacrolimus.5 The company targets four transplant indications — kidney, islet cell, liver, and xenotransplantation — plus amyotrophic lateral sclerosis (ALS), with tegoprubart as its sole clinical asset.
The fundamentals picture is characteristic of a late-preclinical/early-clinical-stage biotech: no revenue, a widening cash burn ($66.3M in R&D expenses in FY2025),4 and a cash position of $111.1M as of March 31, 2026 that the company says funds operations into Q2 2027.3 The market capitalization of approximately $302M as of mid-June 20261 is driven entirely by optionality on tegoprubart's clinical success. Shares outstanding totaled approximately 75.9M as of March 31, 2026,8 a figure that has grown significantly through repeated equity offerings as the company finances its pipeline.
The bull case rests on two pillars: Phase 2 BESTOW kidney transplant data demonstrating a favorable safety and tolerability profile versus tacrolimus with a mean 12-month eGFR of approximately 69 mL/min/1.73 m²,9 and the remarkable islet cell transplant data in type 1 diabetes — all 10 evaluable patients achieved 100% insulin independence with stable graft function observed over a maximum follow-up of 22 months.6 The bear case centers on a binary Phase 3 outcome risk, near-term dilution as the cash runway expires, the unresolved safety legacy of the CD40L antibody class, and the company's complete dependence on external financing. All 7 covering analysts maintain Buy or Strong Buy ratings with a median price target of $8.50.2
Company History & Leadership
Eledon Pharmaceuticals traces its roots to Novus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on hearing disorders. The pivotal transformation came in September 2020 when the company acquired Anelixis Therapeutics, Inc. — a spinout from the ALS Therapy Development Institute (ALS TDI) in Cambridge, Massachusetts — and pivoted entirely toward the CD40L immunology platform.14 The company subsequently rebranded as Eledon Pharmaceuticals, Inc. in January 2021.14 Today, Eledon is headquartered in Irvine, California, and listed on the Nasdaq Capital Market under the ticker ELDN.5
Corporate Timeline
Leadership
| Name | Title | Background |
|---|---|---|
| Dr. David-Alexandre C. Gros | Chief Executive Officer & Director | CEO since Sep 2020. Previously Co-Founder/CEO of Imbria Pharmaceuticals; President/COO of Neurocrine Biosciences; Chief Business Officer of Alnylam Pharmaceuticals; Chief Strategy Officer of Sanofi, S.A.14 |
| Dr. Steven N. Perrin | Scientific Founder & Board Director | Founder and former CEO of Anelixis Therapeutics; 20+ years in drug development at Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, and Biogen Idec; Director since Sep 2020.14 |
Business Model & Unit Economics
Eledon is a pre-revenue, single-asset clinical-stage biotech. Its entire business model is predicated on advancing tegoprubart through clinical trials, securing regulatory approvals, and ultimately either commercializing the drug independently or licensing/partnering it to a larger pharmaceutical company.
Revenue Lines
Eledon has no product revenue. The company funds its operations exclusively through equity financings and, to a lesser extent, grants and research collaborations. As of Q1 2026, the company had $111.1M in cash, cash equivalents, and short-term investments.3 Operating expenses are dominated by research and development costs, which reached $66.3M in FY2025, reflecting expanded clinical trial activity and manufacturing investment for tegoprubart.4 General and administrative expenses declined slightly in FY2025, suggesting some operating discipline outside of core R&D.4
The Drug: Tegoprubart (AT-1501)
Tegoprubart is a humanized IgG1 monoclonal antibody that binds CD40 ligand (CD40L/CD154), blocking its interaction with CD40 on antigen-presenting cells and thereby inhibiting downstream T-cell activation and immune-mediated rejection.5 This mechanism of action — targeting the CD40-CD40L costimulatory pathway — represents a biologically differentiated approach compared to calcineurin inhibitors (tacrolimus, cyclosporine) that dominate current transplant immunosuppression.
Earlier-generation anti-CD40L antibodies were abandoned due to thromboembolic complications tied to platelet Fc receptor binding. Tegoprubart was specifically engineered to minimize this risk through its IgG1 framework design.12 If this safety differentiation holds at Phase 3 scale, it would be a key commercial differentiator.
Indications and Clinical Pipeline
Eledon is pursuing tegoprubart across five clinical areas:5
- Kidney transplantation: Phase 2 BESTOW complete; Phase 3 design in regulatory discussion with FDA in 2026.7
- Islet cell transplantation (Type 1 Diabetes): Investigator-initiated trial at UChicago Medicine showing compelling insulin independence data.6
- Liver transplantation: Orphan Drug Designation granted; investigator-led study planned.10
- Xenotransplantation: Tegoprubart used as a key component of the immunosuppression regimen in two genetically modified pig-to-human kidney transplants and in the second-ever pig-to-human heart transplant.21
- ALS: Phase 2a study completed, demonstrating safety and target engagement; further investigation warranted in powered placebo-controlled studies.16
Moat and Growth Motion
Eledon's competitive moat rests on: (1) being the first anti-CD40L antibody to enter multiple clinical trials for transplantation;12 (2) a growing body of peer-reviewed clinical evidence; (3) Orphan Drug Designations that confer market exclusivity; and (4) early positioning in xenotransplantation, a potentially transformative field where no approved immunosuppression regimen yet exists. The commercialization path is likely via a partnership with a major transplant-focused pharma or the addition of a commercial infrastructure team if trials succeed. Eledon's existing collaborations with academic medical centers (UChicago Medicine, and the sites involved in xenotransplantation) serve as proof-of-concept validation rather than direct revenue.
Price History & Technicals
| Metric | Value | Notes |
|---|---|---|
| Last Close (Jun 20, 2026) | $3.57 | Mid-range within 52-week band1 |
| 52-Week High | $4.60 | ~Jun 2026 data1 |
| 52-Week Low | $1.35 | ~Summer 2025 trough1 |
| Market Cap (Jun 18, 2026) | ~$302.6M | Small/micro-cap1 |
| Shares Outstanding (Mar 31, 2026) | 75,851,722 | Common shares issued and outstanding8 |
| Exchange | NasdaqCM | Nasdaq Capital Market5 |
ELDN has exhibited high volatility characteristic of a single-asset clinical-stage biotech. The stock reached a 52-week low of approximately $1.35 in summer 2025, likely reflecting cash concerns before the company executed its $85M oversubscribed underwritten offering.11 The subsequent offering and the positive Phase 2 BESTOW data presented at ASN Kidney Week in November 2025 combined to push the stock higher, with the 52-week high reaching $4.60.9
As of the June 20, 2026 close, ELDN was trading at approximately $3.57 — in the middle of its 52-week range and above its 200-day simple moving average.1 The stock is trading in the middle of its 52-week range, which suggests the market is pricing in substantial clinical uncertainty ahead of the critical Phase 3 FDA meeting and Phase 3 trial initiation that management has guided for 2026.7
Price action at this stage is driven almost entirely by binary clinical events. Positive Phase 3 trial design acceptance by the FDA, partnership announcements, additional positive islet or xenotransplantation data, or ALS efficacy signals could each be significant positive catalysts. Conversely, a Phase 3 clinical hold, unexpected safety signals, or dilutive financing at a low price would pressure the stock sharply. The market cap of approximately $302M1 reflects optionality pricing on a potentially large transplant immunosuppression market rather than any fundamental income stream.
Financial Statements & Guidance
Income Statement Summary
| Period | Revenue | R&D Expense | Net Loss | EPS (Basic) |
|---|---|---|---|---|
| FY2024 | — | $52.0M | n/d | n/d |
| FY2025 | — | $66.3M | $(45.6)M | n/d |
| Q1 2026 | — | n/d | $(39.0)M | $(0.33) |
Revenue: Eledon is a development-stage company with no product revenue. FY2024 net loss not disclosed in available sources; R&D figure sourced from FY2025 10-K comparative disclosures. Q1 2026 net loss of $39.0M includes a large non-cash warrant fair value change; excluding that, adjusted Q1 2026 net loss was $20.1M.3 FY2025 net loss aided by a $33.4M non-cash gain on warrant liabilities.4
Balance Sheet Highlights (as of Dec 31, 2025)
- Cash and short-term investments: $133.3M4
- Working capital: $117.3M4
- No product revenue; no disclosed long-term debt4
- Debt to equity: Not meaningful (development-stage, equity-funded)4
Balance Sheet Highlights (as of Mar 31, 2026)
- Cash, cash equivalents & short-term investments: $111.1M3
- Funds operations through: Q2 20273
- Shares outstanding: 75,851,722 common shares8
Forward Guidance
Eledon does not provide revenue guidance (it has no revenue). The company's operational guidance for 2026 includes: seeking FDA guidance on Phase 3 kidney transplant trial design; receiving FDA regulatory guidance on the path to market for tegoprubart in islet cell and xenotransplantation; reporting long-term BESTOW data; and initiating investigator-led studies in liver and islet transplantation.7 The company expects its current cash position to fund operations into Q2 2027, though this timeline is subject to actual clinical spending rates.3
Sell-Side View
Sell-side sentiment on ELDN is uniformly bullish, with all covering analysts rating the stock a Buy or Strong Buy as of June 2026. The consensus reflects high conviction in tegoprubart's clinical differentiation, particularly following the Phase 2 BESTOW data and the striking islet transplant results in type 1 diabetes.
As of June 9, 2026, the analyst consensus was Strong Buy based on 7 analysts, all of whom maintained Buy ratings with 0 Hold and 0 Sell ratings.2 The average price target across sources ranged from approximately $7.33 to $9.67, with a commonly cited median target of $8.50.2 The high end of the target range reached $12.00, while the most conservative analyst set a target of $4.00.2 At a last close of approximately $3.57, the consensus average target implies approximately 129% upside.
| Metric | Value | Source / Notes |
|---|---|---|
| Consensus Rating | Strong Buy | As of Jun 9, 20262 |
| Number of Analysts | 7 | All Buy / Strong Buy2 |
| Average Price Target | $8.16 | Wall Street consensus2 |
| Median Price Target | $8.50 | Based on 7 analysts2 |
| High Target | $12.00 | Most bullish analyst2 |
| Low Target | $4.00 | Most conservative analyst2 |
| Implied Upside (avg PT) | ~129% | vs. $3.57 close1 |
The wide target range ($4.00–$12.00) reflects significant dispersion in how analysts model the probability-weighted value of the tegoprubart franchise. The low-end target at $4.00 is barely above the current price, suggesting that at least one analyst prices in substantial dilution risk and clinical failure probability. The $12.00 high target implies a successful Phase 3 kidney transplant approval and meaningful islet cell or xenotransplantation revenue. Covering analysts have reportedly presented at the Leerink Partners Healthcare Conference, where management discussed strategic insights on transplantation.22
Morningstar fair value was not available in sources reviewed at the time of this brief. The analyst community's uniform Buy stance is a strong signal but should be weighted against the fact that all-Buy situations in micro-cap clinical-stage biotechs are common and do not guarantee positive clinical outcomes. Earnings estimate consensus is not meaningful for a development-stage company with no revenue.
Partnerships, Customers & Suppliers
Site of the investigator-initiated islet cell transplant trial in type 1 diabetes. All 10 evaluable patients achieved 100% insulin independence with tegoprubart-based immunosuppression, with stable graft function over a maximum 22-month follow-up.6
Zurich-based NewcelX partnered with Eledon to evaluate tegoprubart paired with NCEL-101, a stem-cell-derived islet therapy, as a potential functional cure for type 1 diabetes. NewcelX submitted an NCEL-101 pre-IND briefing package to the FDA in May 2026.23
Tegoprubart was used as a key component of the immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human and in the second-ever transplant of a genetically modified pig heart to a human patient.21
Anelixis Therapeutics, the company that brought tegoprubart into Eledon via the 2020 acquisition, was spun out of ALS TDI in Cambridge, Massachusetts. The scientific lineage of tegoprubart traces to ALS TDI's CD40L biology program.14
Eledon presented new long-term data from the Phase 2 BESTOW extension study at ATC 2026 (June 20–24, 2026), using the congress as a key channel for scientific validation and investor awareness.19
Leerink has hosted Eledon management at healthcare conferences, providing institutional investor access. Eledon's underwritten offerings have been supported by investment banks helping place shares to institutional investors.22
Eledon does not have a commercial product and therefore has no customer concentration risk in the traditional sense. Its "customer" base at this stage consists of clinical trial sites, academic medical centers, and investigator-sponsors. The company's partnerships are largely academic/investigator-driven rather than commercial, which is appropriate for its development stage. A major commercial partnership with a large transplant-focused pharma company — similar to what Alexion, Novartis, or Roche do in rare disease — would be a transformative catalyst that does not yet appear imminent based on public disclosures.
Competition
Eledon operates in the transplant immunosuppression market, a space dominated by decades-old calcineurin inhibitor (CNI) regimens (tacrolimus, cyclosporine) and mTOR inhibitors, all of which carry significant long-term toxicity burdens including nephrotoxicity, neurotoxicity, and metabolic complications. Tegoprubart's differentiation thesis is built on providing equivalent or superior immunosuppression with a meaningfully cleaner side-effect profile — targeting a fundamentally different pathway (CD40-CD40L costimulation) than existing approved therapies.
| Company / Asset | Public? | Mechanism | Stage / Setting | Key Differentiator vs. ELDN |
|---|---|---|---|---|
| Calcineurin inhibitors (Tacrolimus/Cyclosporine) | Generic/Multi-co. | CNI — calcineurin inhibition | Approved standard-of-care | Entrenched SoC; nephrotoxic; tegoprubart designed to replace, not compete alongside9 |
| Tonix Pharmaceuticals — TNX-1500 | Public (TNXP) | Anti-CD40L antibody | Preclinical / early clinical | Same class; Eledon further advanced in clinical development24 |
| Dazodalibep (HZN-4920) — Horizon/Amgen | Amgen (AMGN) | CD40L antagonist fusion protein | Clinical (Sjögren's, autoimmune) | Different indication focus; Amgen's resources dwarf Eledon's24 |
| BNZ312 (GEN 1042) | Private/Genmab | CD40 agonist (oncology) | Clinical | Different mechanism (agonist, not antagonist); oncology focus24 |
| Belatacept (Bristol-Myers Squibb) | BMS (BMY) | CTLA4-Ig (CD28/B7 pathway) | Approved (kidney transplant) | Different costimulatory pathway; approved alternative to CNIs; possible combination partner24 |
Tegoprubart's key competitive advantages in kidney transplantation center on: (1) the demonstrated safety profile in Phase 2 BESTOW with significantly reduced metabolic, neurologic, and cardiovascular toxicities compared to tacrolimus;9 (2) being the first anti-CD40L antibody to enter multiple clinical trials for transplantation patients;12 and (3) early positioning across multiple transplant indications that provides portfolio breadth a single-indication competitor cannot match.
The most important competitive risk is that the CD40L pathway, while scientifically compelling, has a long history of failed or abandoned development programs, primarily due to the thromboembolic risk of earlier antibodies. If tegoprubart's safety differentiation does not hold at Phase 3 scale (thousands of patients over longer timeframes), the competitive thesis collapses regardless of efficacy.
In the islet cell transplantation space for type 1 diabetes, tegoprubart is early but potentially dominant: the 100% insulin independence rate in 10 evaluable patients6 is a clinical signal that would attract significant attention from Vertex (which is developing VX-880 stem-cell-derived islets), Sana Biotechnology (SC451), and potentially CRISPR-based islet replacement companies. The partnership with NewcelX to combine NCEL-101 islets with tegoprubart23 positions Eledon to compete in this emerging space, though the timeline to commercialization in islet transplantation remains very long.
Risks & the Bear Case
Shares outstanding grew approximately 52% year-over-year.11 The $85M offering priced at $3.65/share caused immediate book dilution of $1.50/share for existing holders.11 Additional dilutive financings are near-certain before any revenue generation.
Cash of $111.1M funds operations only into Q2 2027.3 Without a partnership deal, positive Phase 3 data, or another equity raise, the company will be forced to dilute shareholders at potentially unfavorable prices.
The company has not yet initiated a Phase 3 kidney transplant trial, pending FDA design guidance.7 A Phase 3 failure or clinical hold would be potentially catastrophic for a company with a single clinical asset and no revenue.
Earlier anti-CD40L antibodies were abandoned due to thromboembolic complications. Tegoprubart is designed to mitigate this, but long-term safety in larger patient populations is not yet established.12
Eledon has zero product revenue and has incurred losses since inception. FY2025 R&D expenses of $66.3M alone exceed the company's quarterly cash balance if burn accelerates.4 Commercialization is years away at minimum.
Phase 3 trial design for kidney transplantation is still in FDA discussion as of Q2 2026.7 Regulatory feedback could require a larger, longer, or more expensive trial than anticipated, straining the cash runway further.
Tacrolimus-based regimens are deeply entrenched. Transplant physicians are conservative adopters of new immunosuppression. Even a successful Phase 3 does not guarantee rapid commercial uptake, especially without a large pharma partner for marketing.9
The impressive 100% insulin independence result comes from only 10 evaluable T1D patients in an investigator-initiated trial.6 Small-n results in academic settings frequently fail to replicate in larger randomized trials. Islet transplantation itself remains a complex, non-scalable procedure.
Bear Thesis Deep-Dive
The strongest reasonable bear case for ELDN is a combination of (1) Phase 3 failure or extended delay and (2) dilution at low prices as the cash runway expires. Here is how this scenario could play out:
Eledon's cash of $111.1M as of Q1 2026 funds operations into Q2 2027.3 If the FDA Phase 3 design discussion drags into late 2026 — which is possible given the complexity of transplant trial design (endpoints, comparator arms, duration, patient population) — trial initiation could slip to 2027. Phase 3 kidney transplant trials typically take several years to enroll and read out; a realistic timeline to a Phase 3 readout might be 2029–2030 even under an optimistic scenario. This means Eledon needs at least two or three more major financing rounds before any potential approval, each of which will dilute existing shareholders — the $85M offering in late 2025 already caused $1.50/share of immediate book dilution.11
Meanwhile, the company's most dramatic data point — 100% insulin independence in 10 islet transplant patients6 — while extraordinary, comes from an investigator-initiated academic trial with a very small n. Small-n results in transplantation frequently fail to replicate when scrutinized in randomized controlled trials at multiple sites. If the islet story loses momentum, the market would have to re-rate ELDN purely on its kidney transplant program — where it is still years from approval and faces the entrenched tacrolimus standard of care.
Finally, the CD40L class carries a historical shadow: earlier antibodies (MR1, 5c8) were halted in the early 2000s due to thromboembolic events believed to be Fc-receptor-mediated. Eledon has engineered tegoprubart to minimize this, and the Phase 2 data has been encouraging, but the mechanism has not yet been tested in thousands of patients over multi-year periods.12 A late-stage safety signal would be catastrophic. The bear case is not that tegoprubart is a bad drug — it may well be transformative. The bear case is that the binary event risk, combined with dilution pressure and a ~2027 funding cliff, leaves limited margin of safety at the current ~$302M valuation.
Catalysts — Recent & Upcoming
Recent Events (Last 90 Days)
Upcoming Watch List
| Event | Expected Timing | Notes |
|---|---|---|
| FDA meeting — Phase 3 kidney transplant trial design | H2 2026 | Key regulatory gating milestone; FDA feedback will determine trial size, duration, endpoint selection7 |
| Phase 3 kidney transplant trial initiation | 2026 (subject to FDA guidance) | Conditional on FDA alignment; initiation announcement would be major stock catalyst7 |
| FDA regulatory guidance — islet cell transplantation path to market | 2026 | FDA views on commercialization pathway for islet TX indication; could accelerate or complicate development7 |
| Investigator-led liver transplant study initiation | 2026 | Extends tegoprubart's clinical breadth; supported by Orphan Drug Designation7 |
| NewcelX NCEL-101 pre-IND progress | 2026–2027 | NewcelX filed pre-IND package with FDA in May 2026; IND approval would accelerate the T1D combination therapy timeline23 |
| Next equity offering / financing | Before Q2 2027 | Cash runway expires Q2 2027; additional capital raise is highly likely given burn rate3 |
| Q2 2026 earnings release | Aug 2026 (est.) | Will include updated cash position, potential regulatory updates, and any new clinical data3 |
References
- Eledon Pharmaceuticals (ELDN) Stock Price & Overview Stock Analysis · Jun 2026
- Eledon Pharmaceuticals (ELDN) Stock Forecast and Price Target 2026 MarketBeat · Jun 2026
- Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights Eledon Pharmaceuticals IR · May 13, 2026
- Eledon Pharmaceuticals, Inc. — Form 10-K — FY2025 SEC EDGAR · 2026
- Eledon Pharmaceuticals (ELDN) Company Profile & Description Stock Analysis · 2026
- Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine Eledon Pharmaceuticals IR · 2026
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook Eledon Pharmaceuticals IR · Jan 8, 2026
- Eledon Pharmaceuticals, Inc. — Form 10-Q — FY2026 (Q1) SEC EDGAR · 2026
- Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at ASN Kidney Week 2025 Eledon Pharmaceuticals IR · Nov 2025
- Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation Eledon Pharmaceuticals IR · 2026
- Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Eledon Pharmaceuticals IR · 2025
- Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer Drug Development · 2024
- Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire / Eledon · May 13, 2026
- Eledon Pharmaceuticals, Inc. (ELDN): history, ownership, mission, how it works & makes money DCF Modeling · 2025
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation Eledon Pharmaceuticals IR · 2025
- Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial PMC / NIH · Oct 2024
- Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart Following Islet Transplantation at UChicago Medicine Eledon Pharmaceuticals IR · 2024
- Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants Eledon Pharmaceuticals IR · Sep 2024
- Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress Eledon Pharmaceuticals IR · Jun 2026
- Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at ADA 2026 Scientific Sessions Eledon Pharmaceuticals IR · Jun 2026
- Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human Eledon Pharmaceuticals IR · 2024–2025
- Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation Investing.com / Leerink Partners · 2026
- NewcelX, Eledon to pair stem cell therapy with CD40 mAb against type 1 diabetes AllSci · 2026
- CD40/CD40L Inhibitors Market Size, Drugs, Companies, Insights DelveInsight · 2024–2025